AstraZeneca's (AZN.US) "Osimertinib" has been approved for a new indication in China.
Generated by AI AgentMarket Intel
Thursday, Jan 2, 2025 8:30 am ET1min read
On January 2, the National Administration for Drug Regulation's website announced that the new indication of osimertinib (AZN.US) was officially approved for the treatment of adult patients with locally advanced unresectable (III stage) non-small cell lung cancer (NSCLC) who have not progressed after receiving platinum-based curative radiotherapy and chemotherapy and have epidermal growth factor receptor (EGFR) exon 19 deletion (Ex19del) or exon 21 (L858R) substitution mutations.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet